Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BESAFE: Bempedoic Acid with PCSK9 Inhibitors and Ezetimibe in Statin-Intolerant Patients
NCT06381947Phase 4Not yet recruiting
- Sponsor
- University of Salerno
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of bempedoic acid in dyslipidemia (2 arms), sponsored by University of Salerno. Primary endpoint: Mean percentage change in LDL-C at 12 weeks. Planned start May 2024; status: not yet recruiting.
02
Drugs
bempedoic acid
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06381947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381947.